The role of leukemia inhibitory factor in autoimmune disorders: insights into recovery and treatment.

IF 1.2 Q4 RHEUMATOLOGY

Reumatismo Pub Date : 2025-04-01 DOI:10.4081/reumatismo.2025.1753

Zahra Rodgarpoor, Ahmad Meshkin, Mohammadamin Ehramianpour, Fateme Zare

{"title":"The role of leukemia inhibitory factor in autoimmune disorders: insights into recovery and treatment.","authors":"Zahra Rodgarpoor, Ahmad Meshkin, Mohammadamin Ehramianpour, Fateme Zare","doi":"10.4081/reumatismo.2025.1753","DOIUrl":null,"url":null,"abstract":"Objective: Leukemia inhibitory factor (LIF) is a multifunctional cytokine involved in numerous physiological processes, including inflammation and immune response regulation. Recent studies have highlighted its potential role in the pathogenesis and treatment of autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS). This review aims to investigate the role of LIF in various autoimmune disorders and its impact on the recovery and treatment of these diseases.Methods: A comprehensive literature search was conducted using Google Scholar, PubMed, and Scopus databases. Relevant studies published up to December 2023 were identified using keywords such as \"leukemia inhibitory factor\", \"autoimmune diseases\", \"rheumatoid arthritis\" and \"multiple sclerosis\".Results: The literature indicates that LIF has a dual role in autoimmune diseases. In RA, LIF plays an important role in the progression of joint damage by increasing the inflammatory response. In MS, LIF has been shown to promote remyelination and neuroprotection, suggesting its potential as a therapeutic agent. However, the precise mechanisms by which LIF modulates immune responses in these conditions remain incompletely understood.Conclusions: LIF represents a promising target for treating autoimmune diseases, particularly RA and MS. Further research is required to elucidate its mechanisms of action and develop targeted therapies that can control its beneficial effects while minimizing potential adverse outcomes.","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatismo","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/reumatismo.2025.1753","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Leukemia inhibitory factor (LIF) is a multifunctional cytokine involved in numerous physiological processes, including inflammation and immune response regulation. Recent studies have highlighted its potential role in the pathogenesis and treatment of autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS). This review aims to investigate the role of LIF in various autoimmune disorders and its impact on the recovery and treatment of these diseases.

Methods: A comprehensive literature search was conducted using Google Scholar, PubMed, and Scopus databases. Relevant studies published up to December 2023 were identified using keywords such as "leukemia inhibitory factor", "autoimmune diseases", "rheumatoid arthritis" and "multiple sclerosis".

Results: The literature indicates that LIF has a dual role in autoimmune diseases. In RA, LIF plays an important role in the progression of joint damage by increasing the inflammatory response. In MS, LIF has been shown to promote remyelination and neuroprotection, suggesting its potential as a therapeutic agent. However, the precise mechanisms by which LIF modulates immune responses in these conditions remain incompletely understood.

Conclusions: LIF represents a promising target for treating autoimmune diseases, particularly RA and MS. Further research is required to elucidate its mechanisms of action and develop targeted therapies that can control its beneficial effects while minimizing potential adverse outcomes.

查看原文本刊更多论文

白血病抑制因子在自身免疫性疾病中的作用：对恢复和治疗的见解。

目的：白血病抑制因子（Leukemia inhibitory factor， LIF）是一种参与多种生理过程的多功能细胞因子，包括炎症和免疫反应调节。最近的研究强调了其在自身免疫性疾病如类风湿关节炎（RA）和多发性硬化症（MS）的发病机制和治疗中的潜在作用。本文旨在探讨LIF在各种自身免疫性疾病中的作用及其对这些疾病的恢复和治疗的影响。方法：采用谷歌Scholar、PubMed、Scopus数据库进行综合文献检索。截至2023年12月发表的相关研究使用“白血病抑制因子”、“自身免疫性疾病”、“类风湿关节炎”和“多发性硬化症”等关键词进行识别。结果：文献表明，LIF在自身免疫性疾病中具有双重作用。在类风湿性关节炎中，liff通过增加炎症反应在关节损伤的进展中起重要作用。在多发性硬化症中，LIF已被证明可促进髓鞘再生和神经保护，表明其作为一种治疗药物的潜力。然而，在这些条件下，LIF调节免疫反应的确切机制仍然不完全清楚。结论：LIF是治疗自身免疫性疾病，特别是RA和ms的一个有希望的靶点，需要进一步的研究来阐明其作用机制，并开发靶向治疗，以控制其有益作用，同时最大限度地减少潜在的不良后果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reumatismo RHEUMATOLOGY-

CiteScore

2.10

自引率

7.10%

发文量

审稿时长

10 weeks

期刊介绍： Reumatismo is the official Journal of the Italian Society of Rheumatology (SIR). It publishes Abstracts and Proceedings of Italian Congresses and original papers concerning rheumatology. Reumatismo is published quarterly and is sent free of charge to the Members of the SIR who regularly pay the annual fee. Those who are not Members of the SIR as well as Corporations and Institutions may also subscribe to the Journal.